AgeX Therapeutics, Inc. Contracts & Agreements
79 Contracts & Agreements
- Business Finance (54 contracts)
- Business Operations (1)
- Human Resources (10)
- Mergers & Acquisitions (2)
- Real Estate (1)
- Uncategorized (11)
- Stock Purchase Agreement dated December 23, 2024, between Serina Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on December 26, 2024)
- Serina Therapeutics (Filed With SEC on December 18, 2024)
- Confidential Consulting Agreement, dated as of May 31, 2024, by and between Serina Therapeutics, Inc. and FLG Partners, LLC (Filed With SEC on November 12, 2024)
- Employment Agreement, dated as of July 15, 2024, by and between Serina Therapeutics, Inc. and Srini Tenjarla (Filed With SEC on November 12, 2024)
- Employment Agreement, effective as of September 9, 2024, among Serina Therapeutics, Inc., Serina Therapeutics (AL), Inc. and Steve Ledger (Filed With SEC on September 12, 2024)
- Eighth Amendment to Amended and Restated Convertible Promissory Note dated May 8, 2024, between UniverXome Bioengineering, Inc. and Juvenescence Limited (Filed With SEC on May 14, 2024)
- Executive Chairman Agreement (Filed With SEC on April 17, 2024)
- Asset Contribution Agreement dated March 26, 2024 between AgeX Therapeutics, Inc. and UniverXome Bioengineering, Inc (Filed With SEC on April 1, 2024)
- Allonge and Seventh Amendment to Amended and Restated Convertible Promissory Notes dated March 26, 2024, among AgeX Therapeutics, Inc., the Guarantors party thereto and... (Filed With SEC on April 1, 2024)
- Agreement with respect to Convertible Notes dated March 26, 2024, among AgeX Therapeutics, Inc., UniverXome Bioengineering, Inc., the Subsidiary Obligors and Juvenescence Limited (Filed With SEC on April 1, 2024)
- Form of Indemnification Agreement for Officers and Directors (Filed With SEC on April 1, 2024)
- Director Compensation Policy (Filed With SEC on April 1, 2024)
- Serina Therapeutics, Inc. 2017 Stock Option Plan (Filed With SEC on April 1, 2024)
- Form of Stock Option Agreement (Filed With SEC on April 1, 2024)
- Warrant Agreement, dated March 19, 2024 between AgeX Therapeutics, Inc. and Equinity Trust Company, LLC (Filed With SEC on March 22, 2024)
- Form of Incentive Warrant included in Warrant Agreement dated March 19, 2024 (Filed With SEC on March 22, 2024)
- Form of Post-Merger Warrant included in Warrant Agreement dated March 19, 2024 (Filed With SEC on March 22, 2024)
- Sixth Amendment to Amended and Restated Convertible Promissory Note, dated February 9, 2024, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 14, 2024)
- Guaranty Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc. and Juvenescence Limited (Filed With SEC on November 14, 2023)
- Amended and Restated Certificate of Designation of Series A Preferred Stock (Filed With SEC on November 14, 2023)
- Amended and Restated Certificate of Designation of Series B Preferred Stock (Filed With SEC on November 14, 2023)
- Amendment to Transition Services and Separation Agreement, dated October 31, 2023, between AgeX Therapeutics, Inc. and Michael D. West (Filed With SEC on November 14, 2023)
- Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note, dated November 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on November 14, 2023)
- Form of Pledge Agreement by AgeX Therapeutics, Inc (Filed With SEC on November 14, 2023)
- Guaranty Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc. and Juvenescence Limited (Filed With SEC on November 14, 2023)
- Joinder Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc., AgeX Therapeutics, Inc. and... (Filed With SEC on November 14, 2023)
- Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note, dated November 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on November 14, 2023)
- Form of Pledge Agreement by AgeX Therapeutics, Inc (Filed With SEC on November 14, 2023)
- Joinder Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc., AgeX Therapeutics, Inc. and... (Filed With SEC on November 14, 2023)
- Letter Agreement, dated August 29, 2023, by and among AgeX Therapeutics, Inc., Serina Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on August 30, 2023)
- Form of Serina Therapeutics, Inc. Lock-Up Agreement (Filed With SEC on August 30, 2023)
- Form of AgeX Therapeutics, Inc. Lock-Up Agreement (Filed With SEC on August 30, 2023)
- Form of Serina Therapeutics, Inc. Stockholder Support Agreement (Filed With SEC on August 30, 2023)
- Form of AgeX Therapeutics, Inc. Stockholder Support Agreement (Filed With SEC on August 30, 2023)
- Agreement and Plan of Merger and Reorganization, dated August 29, 2023, by and among AgeX Therapeutics, Inc., Canaria Transaction Corporation and Serina Therapeutics, Inc (Filed With SEC on August 30, 2023)
- Consulting Agreement, dated August 9, 2023, between AgeX Therapeutics, Inc. and Joanne Hackett (Filed With SEC on August 14, 2023)
- Transition Services and Separation Agreement, dated August 9, 2023, between AgeX Therapeutics, Inc. and Michael D. West (Filed With SEC on August 14, 2023)
- Amendment to Secured Convertible Promissory Note, executed by AgeX Therapeutics, Inc. and Juvenescence Limited on July 31, 2023 (Filed With SEC on August 4, 2023)
- Fourth Amendment to Amended and Restated Secured Convertible Promissory Note, executed by AgeX Therapeutics, Inc. and Juvenescence Limited on July 31, 2023 (Filed With SEC on August 4, 2023)
- Registration Rights Agreement, dated July 21, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on July 21, 2023)
- Exchange Agreement, dated July 21, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on July 21, 2023)
- Form of Certificate of Designation of Series B Preferred Stock (Filed With SEC on July 21, 2023)
- Form of Certificate of Designation of Series A Preferred Stock (Filed With SEC on July 21, 2023)
- Third Amendment to Amended and Restated Secured Convertible Promissory Note, dated June 2, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on June 8, 2023)
- Allonge and Second Amendment to Amended and Restated Convertible Promissory Note dated May 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on May 12, 2023)
- Description of Securities (Filed With SEC on March 31, 2023)
- Convertible Promissory Note, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc (Filed With SEC on March 15, 2023)
- Secured Convertible Promissory Note dated March 13, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 15, 2023)
- Amended and Restated Security Agreement, dated March 13, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 15, 2023)
- Convertible Note Purchase Agreement, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc (Filed With SEC on March 15, 2023)
- Subordination Agreement, dated March 15, 2023, between AgeX Therapeutics, Inc., Serina Therapeutics, Inc. and the other investors signatory thereto (Filed With SEC on March 15, 2023)
- Third Amendment to that certain Secured Convertible Facility Agreement, dated March 30, 2020, by and between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 15, 2023)
- Reaffirmation Agreement, dated February 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 10, 2023)
- Amended and Restated Secured Convertible Promissory Note, dated February 9, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 10, 2023)
- Amendment of 2017 Equity Inventive Plan (Filed With SEC on December 12, 2022)
- Secured Note dated February 14, 2022, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)
- Form of Warrant (Filed With SEC on February 15, 2022)
- Security Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)
- Warrant Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)
- Amendment No. 3 to Registration Rights Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)
- Amendment No. 2 to Loan Facility Agreement, dated November 8, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on November 9, 2021)
- Plan and Agreement of Merger, dated March 6, 2021, among Atlas Capital Partners Limited, GCLMS Acquisition Corporation, AgeX Therapeutics, Inc., and LifeMap Sciences, Inc (Filed With SEC on March 8, 2021)
- Amendment No. 2 to Registration Rights Agreement, dated February 10, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 11, 2021)
- Amendment No. 1 to Loan Facility Agreement, dated February 10, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 11, 2021)
- Second Amendment to Secured Convertible Facility Agreement, dated November 12, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on November 16, 2020)
- First Amendment to Warrant Agreement, dated July 21, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited, including form of warrant (Filed With SEC on August 14, 2020)
- First Amendment to Secured Convertible Facility Agreement, dated July 21, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on August 14, 2020)
- Employment Agreement, by and between AgeX Therapeutics, Inc. and Andrea E. Park, dated May 15, 2020 (Filed With SEC on August 14, 2020)
- Amendment No. 1 to Registration Rights Agreement, dated March 30, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 30, 2020)
- Warrant Agreement, dated March 30, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited, including form of warrant (Filed With SEC on March 30, 2020)
- Secured Convertible Facility Agreement, dated March 30, 2020, by and among AgeX Therapeutics, Inc., ReCyte Therapeutics, Inc., Reverse Bioengineering, Inc., and Juvenescence... (Filed With SEC on March 30, 2020)
- Description of Securities (Filed With SEC on March 30, 2020)
- Registration Rights Agreement, dated August 13, 2019, between AgeX Therapeutics, Inc. and Juvenescence, Ltd (Filed With SEC on August 14, 2019)
- Warrant Agreement, dated August 13, 2019, between AgeX Therapeutics, Inc. and Juvenescence, Ltd (Filed With SEC on August 14, 2019)
- Loan Facility Agreement, dated August 13, 2019, between AgeX Therapeutics, Inc. and Juvenescence, Ltd (Filed With SEC on August 14, 2019)
- Warrant dated August 13, 2019 (Filed With SEC on August 14, 2019)
- Compensation Agreement, dated March 1, 2019, between AgeX Therapeutics, Inc. and Russell L. Skibsted (Filed With SEC on May 15, 2019)
- Standard Sublease, dated for reference March 13, 2019, between AgeX Therapeutics, Inc. and InSite Vision, Inc (Filed With SEC on May 15, 2019)
- Warrant Agreement, dated February 28, 2018, including form of warrant (Filed With SEC on April 1, 2019)
